Magnolol Potentiates Sorafenib-induced Apoptosis and Inhibits Metastatic Signaling in Renal Carcinoma Authors: CHE-CHENG CHANG, MAN-YUN HUNG, YUEH-SHAN WENG, CHIEH-MIN CHANG, FEI-TING HSU, YU-HSIANG CHEN, JIANN-HWA CHEN Published: 2026 ABSTRACT Background/AimSorafenib is a standard targeted therapy for renal cell carcinoma; however, resistance and limited efficacy remain clinical challenges. Magnolol, a bioactive compound derived from Magnolia officinalis, exhibits anti-cancer properties, and may enhance therapeutic responses. This study investigated whether magnolol potentiates the anti-tumor effects of sorafenib in murine renal carcinoma (Renca) cells and explored the underlying molecular mechanisms.Materials and MethodsCell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and drug interactions were analyzed using the Chou-Talalay method. Apoptosis was evaluated by Annexin V/propidium iodide (PI) staining, cell-cycle analysis, and caspase activation. Western blotting and flow cytometry were performed to examine apoptotic pathways and epidermal growth factor receptor (EGFR)/SRC proto-oncogene, non-receptor tyrosine kinase (SRC)/nuclear factor kappa B (NF-κB) signaling. Transwell assays and protein expression profiling were used to analyze migration, invasion, and epithelial-mesenchymal transition (EMT) markers.ResultsCombination treatment synergistically reduced cell viability, with a combination index (CI) <1, and significantly enhanced apoptosis via activation of intrinsic and extrinsic pathways. Co-treatment suppressed EGFR/SRC proto-oncogene, SRC/ NF-κB signaling and reduced migration, invasion, and EMT-associated markers.ConclusionMagnolol enhances sorafenib efficacy by promoting apoptosis and inhibiting survival and metastatic signaling pathways in renal carcinoma cells. Introduction Renal cell carcinoma (RCC) is one of the most prevalent malignancies of the urinary system, accounting for approximately 2-3% of all adult cancers worldwide. While recent advancements in targeted therapy and immunotherapy have significantly altered the treatment landscape, the clinical management of metastatic RCC (mRCC) remains a formidable challenge (1). Dysregulation of receptor tyrosine kinase (RTK) signaling pathways is a fundamental driver of RCC progression, survival, and metastasis. Within this signaling network, the epidermal growth factor receptor (EGFR) and its downstream effector, SRC proto-oncogene, non-receptor tyrosine kinase (SRC), have emerged as pivotal mediators (2). Activation of the EGFR/SRC axis orchestrates a cascade of oncogenic processes, including accelerated tumor proliferation, tissue invasion, and pathological angiogenesis. Furthermore, this pathway is increasingly recognized as a key contributor to therapeutic resistance, making it a high-priority target for overcoming current treatment limitations in advanced RCC (3, 4). EGFR overexpression has been correlated with aggressive clinicopathological features and unfavorable survival outcomes in RCC (5). SRC, a non-receptor tyrosine kinase, acts as a critical co-activator by interacting functionally with EGFR to amplify downstream oncogenic cascades. This synergistic cross-talk robustly activates the NF-B pathway, a master regulator of the pro-survival response, thereby enhancing tumor cell viability, anti-apoptotic resistance, and metastatic potential (6, 7). Sorafenib, a multi-kinase inhibitor targeting RAF kinases, VEGFR, and PDGFR, has been widely used in advanced RCC treatment (8). Although sorafenib improves progression-free survival, its long-term efficacy is limited by acquired resistance and compensatory activation of alternative survival pathways (9). Emerging evidence suggests that incomplete suppression of EGFR/SRC signaling may contribute to therapeutic escape and tumor progression during sorafenib treatment (10). Therefore, combination strategies that simultaneously inhibit survival signaling pathways may enhance its anti-tumor efficacy. Magnolol, a prominent bioactive polyphenolic compound isolated from Magnolia officinalis, has garnered significant attention for its multifaceted anti-cancer properties (11-14). Extensive evidence indicates that magnolol exerts its therapeutic effects by robustly inducing apoptosis, arresting cell proliferation, and suppressing the epithelial-mesenchymal transition (EMT) (15, 16). Notably, magnolol has been reported to interfere with EGFR- and NF-κB-mediated signaling cascades in various cancer models (17-19), suggesting its potential to complement targeted therapies. Given the pivotal role of the EGFR/SRC/NF-κB axis in RCC progression and therapeutic resistance, we hypothesized that Magnolol may enhance the anti-tumor activity of sorafenib by concurrently suppressing survival signaling and promoting apoptosis. The aim of this study was to investigate the synergistic effects of sorafenib and magnolol in murine renal carcinoma cells and to elucidate the underlying molecular mechanisms, with particular emphasis on apoptosis induction and inhibition of the EGFR/SRC/NF-κB pathway. Materials and Methods Cell culture. Renca murine renal carcinoma cells were cultured in RPMI-1640 Medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 1% non-essential amino acids (NEAA), and 1% sodium pyruvate at 37°C in a humidified atmosphere containing 5% CO₂ (20). Reagents and antibodies.Sorafenib was purchased from Selleckchem (Houston, TX, USA) and dissolved in dimethyl sulfoxide (DMSO). Magnolol was obtained from Sigma-Aldrich (St. Louis, MO, USA) and prepared as a stock solution in DMSO prior to dilution in culture medium for experimental use. Primary antibodies were obtained from the following commercial sources: c-FLIP from Abnova (Taipei, Taiwan, ROC); MCL-1 from BioViosion (Milpitas, CA, USA); MMP-2, MMP-9, and VEGF-A from Abcam (Cambridge, UK); and phospho-EGFR, EGFR, phospho-SRC, SRC, phospho-NF-κB, NF-κB, Cyclin D1, Vinculin, β-actin, E-cadherin, N-cadherin, ZEB1, ZEB2 and XIAP from Cell Signaling Technology (Danvers, MA, USA). Detail information is listed in Table I. Table IReagents that used in this study.DAPI, 4′,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; EGFR, epidermal growth factor receptor; NEAA, non-essential amino acids; NF-κB, nuclear factor kappa B; no., number; SRC, SRC proto-oncogene, non-receptor tyrosine kinase. Reagents that used in this study. DAPI, 4′,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; EGFR, epidermal growth factor receptor; NEAA, non-essential amino acids; NF-κB, nuclear factor kappa B; no., number; SRC, SRC proto-oncogene, non-receptor tyrosine kinase. Cell viability assay.Renca cells were seeded at a density of 5 × 10³ cells per well in 96-well plates and treated with sorafenib (2.5, 5, 7.5, 10, or 15 µM), Magnolol (10, 25, 50, 75, or 100 µM), or their combinations for 48 h. Cell viability was determined using the MTT assay. After treatment, the culture medium was replaced with 100 µl of MTT solution (0.5 mg/ml) and incubated for 2 h at 37°C. The resulting formazan crystals were dissolved in DMSO, and absorbance was measured at 570 nm using a SpectraMax iD3 microplate reader (Molecular Devices, San Jose, CA, USA) (21, 22). All experiments were performed in triplicate. Combination index (CI) analysis.Drug interaction effects were evaluated using CompuSyn software (ComboSyn, Paramus, NJ, USA) according to the Chou-Talalay method (23). The combination index (CI) was calculated for each drug concentration pair, where CI <1, CI =1, and CI >1 indicate synergistic, additive, and antagonistic effects, respectively (24). GEPIA analysis. Gene expression and survival analyses were performed using the Gene Expression Profiling Interactive Analysis (GEPIA) web server (http://gepia.cancer-pku.cn), which integrates RNA-seq data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. Expression profiles of renal carcinoma subtypes, including kidney chromophobe (KICH) and kidney renal papillary cell carcinoma (KIRP), were obtained from the TCGA dataset. Overall survival analyses of EGFR were performed using the Kaplan-Meier method. Correlation analysis between EGFR and SRC expression was assessed using Pearson’s correlation coefficient via the “Correlation Analysis” module in GEPIA. Western blotting. Renca cells were treated with magnolol (25 μM), sorafenib (7.5 μM), or the combination (magnolol 25 μM and sorafenib 7.5 μM) for 48 h. After treatment, cells were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed in ice-cold NP-40 lysis buffer (e.g., 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40) supplemented with a protease inhibitor cocktail and phosphatase inhibitors. Lysates were incubated on ice for 30 min with intermittent vortexing and clarified by centrifugation at 14,000 × g for 30 min at 4 °C. Protein concentrations were determined using a BCA protein assay. Equal amounts of protein (typically 20-40 μg) were mixed with 4× Laemmli sample buffer containing reducing agent (β-mercaptoethanol or DTT), heated at 95°C for 5 min, and separated by SDS-PAGE (8-12% gels depending on target molecular weights). Proteins were transferred onto PVDF membranes (pre-activated in methanol) using a wet transfer system at 20 V overnight at 4 °C. Membranes were blocked with 5% non-fat milk in TBST (Tris-buffered saline containing 0.1% Tween-20) for 1 h at room temperature, or with 5% BSA for phosphorylated targets, followed by incubation with primary antibodies against total and phosphorylated EGFR, SRC, and NF-κB p65 (as indicated) overnight at 4 °C. After washing with TBST, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using enhanced chemiluminescence (ECL) reagents and imaged with a chemiluminescence detection system. Band intensities were quantified using ImageJ software. Vinculin or β-actin was used as the loading control for normalization. For phosphorylation analyses, phospho-protein signals were further normalized to the corresponding total protein levels (25, 26). Detail information of antibodies was listed in Table II. Table IIPrimary antibodies that used in this study for Western blotting.c-FLIP, Cellular FLICE-like inhibitory protein; EGFR, epidermal growth factor receptor; MCL-1, myeloid cell leukemia 1; MMP, matrix metalloproteinase; NF-κB, nuclear factor kappa B; no., number; Ser, serine; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; Tyr, tyrosine; VEGF-A, vascular endothelial growth factor A; XIAP, X-linked inhibitor of apoptosis protein; ZEB, zinc finger E-box binding homeobox. Primary antibodies that used in this study for Western blotting. c-FLIP, Cellular FLICE-like inhibitory protein; EGFR, epidermal growth factor receptor; MCL-1, myeloid cell leukemia 1; MMP, matrix metalloproteinase; NF-κB, nuclear factor kappa B; no., number; Ser, serine; SRC, SRC proto-oncogene, non-receptor tyrosine kinase; Tyr, tyrosine; VEGF-A, vascular endothelial growth factor A; XIAP, X-linked inhibitor of apoptosis protein; ZEB, zinc finger E-box binding homeobox. Annexin V/propidium iodide (PI) apoptosis assay. Following treatment of Renca cells with magnolol (25 μM), sorafenib (7.5 μM), or their combination for 48 h, apoptotic cell death was evaluated using a FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA, USA). Cells were harvested, washed with cold PBS, and resuspended in binding buffer. For staining, cells were incubated with Annexin V-FITC (1 μl) and propidium iodide (PI; 2 μl) in 100 μl of binding buffer for 20 min at room temperature in the dark. Fluorescence signals were acquired using a NovoCyte flow cytometer (Agilent Technologies Inc., Santa Clara, CA, USA) and analyzed with NovoExpress® software. Annexin V-FITC fluorescence was detected in the FL-1 channel, while PI fluorescence was detected in the FL-2 channel. Quantitative analysis was performed using FlowJo software (version 7.6.1). Early apoptotic cells were defined as Annexin V-positive and PI-negative, whereas late apoptotic cells were defined as Annexin V-positive and PI-positive populations. Detailed information of staining kits or antibodies is listed in Table III. Table IIIPrimary antibodies used in this study for flow cytometry.DiOC6, 3,3′-dihexyloxacarbocyanine iodide; FasL, Fas ligand; FITC, fluorescein isothiocyanate; no., number; PE, phycoerythrin; PI, propidium iodide; RNase, ribonuclease. Primary antibodies used in this study for flow cytometry. DiOC6, 3,3′-dihexyloxacarbocyanine iodide; FasL, Fas ligand; FITC, fluorescein isothiocyanate; no., number; PE, phycoerythrin; PI, propidium iodide; RNase, ribonuclease. Cell cycle analysis. Cell cycle distribution was examined by propidium iodide (PI) staining followed by flow cytometric analysis. Renca cells were harvested, washed with PBS, and fixed in ice-cold 70% ethanol. Fixed cells were stored at −20°C overnight to ensure proper fixation. Prior to analysis, cells were washed to remove ethanol and incubated with PI staining solution containing RNase A at room temperature for 30 min in the dark. DNA content was subsequently measured using a NovoCyte flow cytometer, and the proportion of cells in different phases of the cell cycle was determined (27). Flow cytometric analysis of caspase activation. Renca cells were plated in 6-well plates at a density of 2 × 10⁵ cells per well and allowed to adhere overnight. Cells were then treated with magnolol (25 μM), sorafenib (7.5 μM), or their combination for 48 h. After treatment, caspase activation was analyzed using the CaspGLOW™ Fluorescein Staining Kit (BioVision) according to the manufacturer’s protocol. Briefly, cells were incubated with fluorogenic probes specific for cleaved caspase-3, caspase-8, and caspase-9 for 30 min at 37 °C. Fluorescence signals corresponding to activated caspases were detected in the FL-1 channel using a NovoCyte flow cytometer (Agilent Technologies Inc) equipped with NovoExpress® software. Quantitative analysis of caspase activation was subsequently performed using FlowJo software (version 7.6.1). Analysis of Fas/FasL activity expression and mitochondrial membrane potential. Renca cells were seeded in 6-well plates at a density of 2 × 10⁵ cells per well and allowed to adhere overnight. Cells were subsequently treated with magnolol (25 μM), sorafenib (7.5 μM), or the combination for 48 h. After treatment, cells were harvested, washed with PBS, and subjected to flow cytometric analysis. For surface expression analysis of Fas and Fas ligand (FasL) (BioLegend, San Diego, CA, USA), cells were incubated with fluorochrome-conjugated anti-Fas and anti-FasL antibodies at room temperature for 30 min in the dark. Following incubation, cells were washed with PBS prior to data acquisition. Mitochondrial membrane potential (ΔΨm) was assessed using the fluorescent probe 3,3′-dihexyloxacarbocyanine iodide (DiOC6). Briefly, treated cells were incubated with DiOC6 staining solution at room temperature for 30 min in the dark, followed by washing with PBS. A decrease in DiOC6 fluorescence intensity was interpreted as loss of mitochondrial membrane potential. All samples were prepared and analyzed as single-color-stained samples. Flow cytometric data were acquired using a NovoCyte flow cytometer equipped with NovoExpress® software (Agilent Technologies Inc.). Quantification of the results was performed using FlowJo 7.6.1 software. Invasion and migration analysis. Renca cells were seeded in 6-well plates at a density of 2 × 10⁵ cells per well and allowed to adhere overnight. Cells were subsequently treated with magnolol (25 μM), sorafenib (7.5 μM), or the combination for 48 h. After treatment, viable cells (2 × 10⁴) were harvested and seeded into Transwell chambers either uncoated (for migration assays) or coated with Matrigel (for invasion assays). Cells were allowed to migrate or invade for 48 h. Following incubation, cells remaining on the upper surface of the membrane were removed, and the cells on the lower surface were fixed with fixative solution (acetic acid:methanol = 1:3) for 15 min and stained with 0.1% crystal violet. The membranes were then examined under a light microscope at 200× magnification. Quantification was performed using ImageJ software (version 1.50; National Institutes of Health, Bethesda, MD, USA), and results were expressed as percentages relative to the respective control group (28). Statistical analysis. All statistical evaluations were conducted using the GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA), and data are expressed as mean±SD from at least three independent biological replicates (n=3). For Western blot analysis, densitometric quantification of protein bands was performed using ImageJ software, with signal intensities normalized to the respective loading controls. Flow cytometry data were analyzed using FlowJo software, employing a consistent gating strategy established based on isotype controls. For comparisons among multiple experimental groups, one-way analysis of variance (ANOVA) was performed. Statistical significance was defined as p<0.05, with higher levels of significance indicated as p<0.01 and p<0.001 where applicable. Results Magnolol enhanced the anti-proliferative effect of sorafenib in Renca cells. to evaluate the cytotoxic effects of sorafenib and magnolol in murine renal carcinoma cells, cell viability assays were performed on Renca cells. Magnolol treatment resulted in a dose-dependent reduction in Renca cell viability (Figure 1A). To investigate the potential synergistic effect of sorafenib and magnolol, we examined the viability of Renca cells upon combination treatment. MTT assays revealed that both sorafenib and magnolol inhibited Renca cell proliferation in a dose-dependent manner. Notably, co-treatment with sorafenib and magnolol resulted in a markedly greater reduction in cell viability compared with either single treatment (Figure 1B). Magnolol synergistically enhances the anti-proliferative and pro-apoptotic effects of Sorafenib in renal carcinoma cells. (A) Renca cells were treated with Magnolol (0-100 μM) for 24 or 48 h, and cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (B) Dose-dependent cytotoxicity of Sorafenib (2.5-10 μM) with or without Magnolol (25 μM) in Renca cells after 48 h of treatment. (C) Combination index (CI) analysis showing the synergistic interaction between Sorafenib and Magnolol calculated using CompuSyn software (CI <1 indicates synergism). (D) Representative Annexin V/propidium iodide (PI) flow cytometry plots showing early and late apoptotic cells after treatment with Sorafenib (7.5 μM), Magnolol (25 μM), or their combination for 48 h. Quantification of total apoptotic cells is shown on the right. (E) Cell cycle analysis indicating the sub-G1 population following treatment as described above. Data are presented as mean±SD of three independent experiments. ***p<0.001 versus control group. To quantitatively determine the nature of the drug interaction, the combination index (18) was calculated using CompuSyn software based on the Chou-Talalay method. The CI values across multiple dose combinations of sorafenib (5-15 µM) with magnolol (25 µM) were consistently below 1, indicating a synergistic anti-proliferative effect (Figure 1C, Table IV). These data demonstrate that Magnolol enhances the sensitivity of Renca cells to sorafenib. Table IVCombination index values. Combination index values. Combined sorafenib and magnolol treatment enhanced apoptosis in Renca cells. to determine whether the observed reduction in cell viability was associated with apoptosis induction, Renca cells were treated with sorafenib (7.5 μM), magnolol (25 μM), or their combination for 48 h and analyzed by Annexin V/PI double staining (Figure 1D). Flow cytometric analysis revealed that the proportion of apoptotic cells significantly increased following combination treatment compared with either single agent. Specifically, the combination group exhibited a marked elevation in both early and late apoptotic populations, with total apoptosis rates exceeding those of sorafenib or magnolol monotherapy (p<0.0001). Quantitative analysis confirmed a synergistic enhancement of apoptosis in the combined treatment group. To further verify apoptotic induction, cell cycle distribution was assessed by flow cytometry following propidium iodide staining (Figure 1E). The combination of sorafenib and magnolol markedly increased the sub-G1 population, indicating DNA fragmentation associated with apoptosis. The sub-G1 fraction in the combination group was significantly higher than that observed in cells treated with either magnolol or sorafenib alone (p<0.0001). These findings collectively demonstrate that co-treatment with sorafenib and magnolol synergistically promotes apoptotic cell death in Renca renal carcinoma cells. Combined sorafenib and magnolol treatment activated mitochondrial and death receptor-mediated apoptosis in Renca cells. To further elucidate the mechanisms underlying the synergistic cytotoxicity of Sorafenib and Magnolol, we assessed the activation of caspase cascades and the involvement of mitochondrial and death receptor-mediated apoptotic pathways in Renca cells. Flow cytometric analysis revealed a significant increase in cleaved caspase-3-positive cells in the combination group compared with either single treatment (Figure 2A). Consistently, the proportion of cells positive for cleaved caspase-9 (Figure 2B) and cleaved caspase-8 (Figure 2F) was markedly elevated in the combination group, suggesting that both intrinsic and extrinsic apoptotic pathways were activated upon co-treatment. Mitochondrial membrane potential (ΔΨm) was then assessed using DiOC₆ staining (Figure 2C). A substantial loss of ΔΨm was observed following combined Sorafenib and Magnolol treatment compared with individual agents (p<0.0001), indicating mitochondrial dysfunction as a key event in apoptosis induction. Furthermore, the expression of death receptor-related proteins was evaluated by flow cytometry. Both Fas (CD95) and Fas ligand (FasL) levels were significantly upregulated in the combination group relative to the control or single-agent treatments (Figure 2D-E), suggesting activation of the Fas/FasL signaling axis. Synergistic activation of both extrinsic and intrinsic apoptotic pathways by the combination of Magnolol and Sorafenib in renal carcinoma cells. Flow cytometric analysis of apoptotic signaling molecules. Renca cells were treated with Magnolol (25 μM), Sorafenib (7.5 μM), or their combination (COMB) for 48 h. (A) Measurement of cleaved caspase-3 activity to evaluate the execution phase of apoptosis. (B) Analysis of cleaved caspase-9 levels to assess the activation of the intrinsic mitochondrial pathway. (C) Assessment of mitochondrial membrane potential (ΔΨm) loss through DiOC6 staining. (D-E) Flow cytometric detection of the cell surface expression of Fas and FasL, markers of the extrinsic death receptor-mediated pathway. (F) Quantification of cleaved caspase-8 levels to confirm extrinsic pathway initiation. (G) Western blot analysis of c-FLIP, MCL-1, and XIAP protein levels. Cell lysates were analyzed by Western blot, with Vinculin serving as the loading control. The quantitative data represents the meaning of three independent experimental replicates. p<0.0001 is considered highly significant. Western blot analysis confirmed that the combination treatment reduced the expression of the anti-apoptotic proteins c-FLIP, MCL-1, and XIAP (Figure 2G), which are known negative regulators of caspase activation. Collectively, these results indicate that co-treatment with Sorafenib and Magnolol induces apoptosis in Renca cells through concurrent activation of the mitochondrial (intrinsic) and death receptor (extrinsic) pathways while suppressing key anti-apoptotic mediators. Combined sorafenib and magnolol treatment suppressed EGFR/SRC/NF-κB signaling in Renca cells. To investigate the molecular mechanisms underlying the synergistic cytotoxicity of Sorafenib and Magnolol, we first examined the clinical relevance of EGFR signaling in renal carcinoma. Analysis of TCGA datasets using the GEPIA platform showed that EGFR expression was significantly higher in tumor tissues than in normal tissues in both KICH and KIRP subtypes (Figure 3A). Moreover, patients with high EGFR expression exhibited poorer overall survival compared with those with low EGFR expression (p=0.026; Figure 3B). Correlation analysis further revealed a positive correlation between EGFR and SRC expression in KICH (R=0.51, p=1×10⁻⁵; Figure 3C), suggesting a co-activation relationship between these two oncogenic kinases in renal cancer progression. Magnolol enhances sorafenib-mediated inactivation of the epidermal growth factor receptor (EGFR)/SRC proto-oncogene, non-receptor tyrosine kinase (SRC)/nuclear factor kappa B (NF-κB) signaling pathway in renal carcinoma cells. (A) EGFR mRNA expression levels in kidney chromophobe (KICH) and kidney renal papillary cell carcinoma (KIRP) tumor tissues. (B) Kaplan-Meier overall survival analysis of KICH and KIRP patients stratified by high and low EGFR expression levels. (C) Pearson correlation analysis between EGFR and SRC expression in KICH patient samples. (D) Protein expression and phosphorylation status of EGFR (Tyr1068), SRC (Tyr416), and NF-κB p65 (Ser536) in Renca cells treated with magnolol (25 μM), sorafenib (7.5 μM), or their combination for 48 h, as determined by Western blotting. Total EGFR, SRC, and NF-κB levels are shown for comparison. Vinculin or β-actin served as the loading control. Representative blots from three independent experiments are shown. Statistical significance is indicated in the figures, with p-values representing comparisons between the control and indicated groups. To experimentally validate the regulatory effects of Sorafenib and Magnolol on these pathways, we performed Western blot analyses in Renca cells following individual or combined treatment (Figure 3D). Co-treatment with Sorafenib (7.5 µM) and Magnolol (25 µM) markedly reduced the phosphorylation levels of EGFR (Tyr1068) and SRC (Tyr416) compared with single-agent treatment. Furthermore, phosphorylation of NF-κB (Ser536), a downstream effector of the EGFR/SRC signaling cascade, was significantly suppressed in the combination group (p=0.0056). These findings demonstrate that Magnolol potentiates the anti-tumor activity of Sorafenib by concurrently inhibiting the EGFR/SRC/NF-κB signaling axis, thereby enhancing apoptosis, and overcoming survival signaling in renal carcinoma cells. Combined sorafenib and magnolol treatment suppressed invasion, migration, and EMT via Inhibition of the EGFR/SRC/NF-κB Axis. To evaluate the functional consequence of EGFR/SRC/NF-κB inhibition on the metastatic potential of renal carcinoma cells, transwell assays were performed to assess cell migration and invasion. As shown in Figure 4A, the combination of Sorafenib (7.5 µM) and Magnolol (25 µM) significantly reduced the migratory and invasive capacities of Renca cells compared with either monotherapy group (p<0.001), indicating a cooperative suppression of tumor cell motility. Inhibitory effects of Magnolol and Sorafenib on the migration, invasion, and epithelial-mesenchymal transition (EMT) of renal carcinoma cells. (A-B) Representative images and quantification of Transwell invasion and migration assays. Renca cells were treated with Magnolol (25 μM), Sorafenib (7.5 μM), or their combination for 48 h. To further investigate the signaling pathways involved, cells were treated with Erlotinib [epidermal growth factor receptor (EGFR) inhibitor], Dasatinib (SRC inhibitor), or QNZ [nuclear factor kappa B (NF-κB) inhibitor]. The number of migrated and invaded cells was quantified and presented as a percentage relative to the control group. (C) Expression of proteins associated with metastasis and proliferation. Protein levels of MMP-2, MMP-9, VEGF-A, and Cyclin D1 were analyzed by Western blotting, with Vinculin or β-actin serving as the internal loading control. (D) Evaluation of the EMT process. To assess the reversal of EMT, the expression of E-cadherin, N-cadherin, ZEB1, and ZEB2 were examined. Vinculin was utilized as the loading control for normalization. To confirm the signaling dependency of this effect, pharmacologic inhibitors targeting EGFR (Erlotinib), SRC (Dasatinib), and NF-κB (QNZ) were employed (Figure 4B). Treatment with these inhibitors recapitulated the suppressive effects observed with the Sorafenib-Magnolol combination, suggesting that the anti-migratory and anti-invasive activities of the combination therapy are mediated through the blockade of the EGFR/SRC/NF-κB signaling pathway. At the molecular level, combination treatment markedly decreased the expression of invasion- and angiogenesis-related proteins MMP-2, MMP-9, and VEGF-A, as well as the cell-cycle regulator Cyclin D1 (Figure 4C). Furthermore, Western blot analysis of EMT markers revealed a significant upregulation of E-cadherin and concomitant downregulation of N-cadherin, ZEB1, and ZEB2 in the combination group (Figure 4D). These results indicate that combined Sorafenib and Magnolol treatment not only inhibits renal carcinoma cell proliferation but also attenuates metastatic progression by reversing EMT and suppressing key pro-invasive and angiogenic mediators through inhibition of the EGFR/SRC/NF-κB pathway. Discussion Magnolol has gained increasing attention not only for its intrinsic anti-cancer activity but also for its ability to enhance the efficacy of conventional therapies (11-14, 29, 30). Sorafenib remains a standard targeted therapy for advanced RCC (8); however, therapeutic resistance and compensatory survival signaling frequently limit its long-term benefit. Our findings support this emerging chemosensitization paradigm in RCC, demonstrating that magnolol significantly potentiates the anti-proliferative effect of sorafenib in Renca cells (Figure 1A-B). The synergistic interaction, confirmed by combination index (CI <1) analysis across multiple dosing ranges (Figure 1C, Table IV), suggests that magnolol may enhance therapeutic efficacy and potentially permit dose reduction of sorafenib while maintaining anti-tumor activity. Previous studies in hepatocellular carcinoma have shown that magnolol can overcome sorafenib resistance through inhibition of STAT3 signaling and induction of oxidative stress (31). Our data extend this concept to RCC and demonstrate that the observed synergy involves coordinated activation of both intrinsic and extrinsic apoptotic pathways. The enhanced apoptotic population detected by Annexin V/PI staining (Figure 1D) and increased sub-G1 fraction (Figure 1E) indicate significant apoptosis induction under combination treatment. Furthermore, activation of cleaved caspase-3, -8, and -9 (Figure 2A, B, F), loss of mitochondrial membrane potential (Figure 2C), and upregulation of Fas/FasL (Figure 2D-E) confirm engagement of both apoptotic cascades. The significant downregulation of anti-apoptotic mediators such as c-FLIP, XIAP, and MCL-1 (Figure 2G) (32) suggests that magnolol lowers the apoptotic threshold, facilitating caspase activation. Similar sensitizing mechanisms have been reported in lung and colorectal cancer models, where magnolol enhances apoptosis via suppression of NF-κB signaling and degradation of c-FLIP (15). Importantly, our study identifies the EGFR/SRC/NF-κB axis as a central mediator of this synergistic effect. TCGA-based analysis demonstrated that EGFR expression is elevated in RCC tumor tissues and correlates with poorer survival (Figure 3A-B). A positive correlation between EGFR and SRC expression was also observed (Figure 3C), consistent with previous evidence indicating that EGFR and SRC co-activation promotes tumor progression and therapeutic resistance (33). Western blot analysis revealed that combination treatment markedly reduced phosphorylation of EGFR (Tyr1068), SRC (Tyr416), and NF-κB (Ser536) (Figure 3D), whereas sorafenib alone achieved only partial suppression. These findings align with reports linking EGFR signaling to NF-κB activation (34), suggesting that SRC-mediated compensatory signaling may contribute to sorafenib resistance (22). Functionally, inhibition of the EGFR/SRC/NF-κB axis translated into significant suppression of migration and invasion (Figure 4A). Pharmacologic inhibition of EGFR (Erlotinib), SRC (Dasatinib), and NF-κB (QNZ) recapitulated these suppressive effects (Figure 4B), confirming pathway dependency. At the molecular level, combination treatment significantly reduced the expression of MMP-2, MMP-9, VEGF-A, and Cyclin D1 (Figure 4C). Moreover, EMT markers were reversed, with upregulation of E-cadherin and downregulation of N-cadherin, ZEB1, and ZEB2 (Figure 4D). Similar chemosensitizing effects have been described for polyphenolic compounds such as curcumin and resveratrol, which suppress NF-κB-mediated signaling and restore epithelial characteristics (25, 35). However, magnolol may be particularly effective in RCC due to its ability to concurrently attenuate upstream receptor tyrosine kinase activation and suppress downstream EMT regulators. Collectively, these findings indicate that magnolol enhances sorafenib efficacy by dismantling compensatory survival and metastatic signaling networks in RCC. By simultaneously activating apoptosis (Figure 1, Figure 2) and suppressing the EGFR/SRC/NF-κB pathway (Figure 3, Figure 4), this combination strategy provides mechanistic support for overcoming resistance and limiting metastatic progression in renal carcinoma. Conflicts of Interest The Authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors’ Contributions C.C.C., M.Y.H., and Y.S.W. performed the experiments, conducted statistical analyses, and compiled the data. C.C.C., M.Y.H., Y.S.W., and C.M.C. contributed to drafting the initial manuscript. Y.H.C. and J.H.C. conceived the study, supervised the research, conducted the literature review, and finalized the manuscript. Funding This study was supported by grants from Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan (Grant No. PTH114037); Cathay General Hospital, Taipei, Taiwan (Grant No. MR-A11305); Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan (Grant No. BRD-111046) and National Science and Technology Council, Taipei, Taiwan (Grant no. NSTC 113-2811-B-039-028, NSTC 114-2811-B-008-002 and NSCT 114-2811-B-008-006). Artificial Intelligence (AI) Disclosure During the preparation of this manuscript, the authors used a large language model (Gemini 3 Flash) to facilitate language editing, grammatical correction, and stylistic refinement of the text. The use of this tool was strictly limited to improving the clarity and readability of the authors’ original content. No portion of the research data –including its generation, statistical analysis, or scientific interpretation– was produced by generative AI. The final manuscript was thoroughly reviewed and verified for accuracy and integrity by the authors, who remain fully responsible for the scientific content. Furthermore, no figures, diagrams, or visual materials were generated or modified using generative AI or machine learning-based image enhancement tools.